A pharmaceutical for preventing or treating a disorder accompanied by ocular angiogenesis and/or increased ocular vascular permeability, constituted by a combination of an anti-VEGF agent, and a hydantoin derivative represented by a general formula (I): (in the formula, X represents a halogen atom or a hydrogen atom, and R 1 and R 2 simultaneously or individually represent a hydrogen atom or an optionally substituted C 1-6 alkyl group), or a pharmacologically acceptable salt thereof.
